Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass.

What Was Tested

The paper reports a study of Growth Hormone, published as a randomized controlled trial.

No randomized controlled trial has been performed on the effects of recombinant human GH on cardiac function in patients with ischemic cardiac failure.

Primary end points were left ventricular ejection fraction and left ventricular mass.

Who Took Part

According to the abstract, 22 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Growth Hormone and who got the comparison, which limits bias.

Left ventricular end-diastolic volume, left ventricular end-systolic volume, and myocardial perfusion, both at rest and during exercise, were assessed as well.

What Was Measured

Primary end points were left ventricular ejection fraction and left ventricular mass.

PubMed files the paper under topics including Growth Hormone, Heart Failure, Hypertrophy, Left Ventricular, Myocardial Ischemia and Ventricular Function, Left.

What This Means in Plain Language

The paper is a randomized study of Growth Hormone in 22 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2001 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the related Exogenous HGH, sermorelin & older GHRPs (why they're passed over) library page, all human trials.